Destiny Pharma PLC
LSE:DEST
Destiny Pharma PLC
Destiny Pharma Plc engages in the discovery, development and commercialization of new antimicrobial products. The company is headquartered in Brighton, Sussex. The company went IPO on 2017-09-04. The firm is engaged in the discovery, development, and commercialization of novel medicines with a focus on infection prevention. The company is focused on developing novel antimicrobial drug from its exeporfinium chloride platform and also from two biotherapeutic products. Its pipeline includes XF-73 nasal gel, NTCD-M3, and XF-73 dermal. XF-73 nasal gel is developed for the prevention of post-surgical staphylococcal infections. NTCD-M3, which is a naturally occurring non-toxigenic strain of C. difficile which lacks the genes that can express C. difficile toxins. NTCD-M3 is used for the prevention of C. difficile infection (CDI) recurrence. XF-73 derma is developed for the prevention and treatment of serious infections associated with wounds and ulcers such as diabetic foot ulcers (DFUs). The firm is co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections.
Destiny Pharma Plc engages in the discovery, development and commercialization of new antimicrobial products. The company is headquartered in Brighton, Sussex. The company went IPO on 2017-09-04. The firm is engaged in the discovery, development, and commercialization of novel medicines with a focus on infection prevention. The company is focused on developing novel antimicrobial drug from its exeporfinium chloride platform and also from two biotherapeutic products. Its pipeline includes XF-73 nasal gel, NTCD-M3, and XF-73 dermal. XF-73 nasal gel is developed for the prevention of post-surgical staphylococcal infections. NTCD-M3, which is a naturally occurring non-toxigenic strain of C. difficile which lacks the genes that can express C. difficile toxins. NTCD-M3 is used for the prevention of C. difficile infection (CDI) recurrence. XF-73 derma is developed for the prevention and treatment of serious infections associated with wounds and ulcers such as diabetic foot ulcers (DFUs). The firm is co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections.
